Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Cancer ; 101(4): 628-36, 2009 Aug 18.
Article in English | MEDLINE | ID: mdl-19672265

ABSTRACT

BACKGROUND: The aim of this study was to evaluate the radiosensitising effect of gemcitabine, in terms of cell-cycle progression, induction of apoptosis, and to investigate the molecular events regulating apoptosis. METHODS: Tumour cells were treated with gemcitabine, radiation, or the combination. 0-72 h after treatment, cells were collected for cell-cycle analysis and apoptosis determination. Caspase 8 and 9, Bid and tBid expression were determined by western blot. The mitochondrial membrane potential was determined using flow cytometry. An RT(2) Profiler PCR Array for human apoptotic genes was performed after the combination or TRAIL treatment. RESULTS: Gemcitabine and radiation resulted in an early S-phase block immediately after treatment, after which the cells moved synchronously through the cell cycle. When cell-cycle distribution returned to pre-treatment levels, an increased induction of apoptosis was observed with activation of caspase 8 and 9 and a reduction of the mitochondrial membrane potential. Gene expression after treatment with radiosensitising conditions was comparable with expression after the TRAIL treatment. CONCLUSION: A role for the cell-cycle perturbations and the induction of apoptosis could be attributed to the radiosensitising effect of gemcitabine. Apoptosis induction was comparable with the apoptotic pathway observed after the TRAIL treatment, that is the involvement of the extrinsic apoptosis pathway.


Subject(s)
Apoptosis/drug effects , Deoxycytidine/analogs & derivatives , Radiation-Sensitizing Agents/pharmacology , Apoptosis/physiology , Apoptosis/radiation effects , BH3 Interacting Domain Death Agonist Protein/drug effects , BH3 Interacting Domain Death Agonist Protein/metabolism , BH3 Interacting Domain Death Agonist Protein/radiation effects , Blotting, Western , Caspase 8/drug effects , Caspase 8/metabolism , Caspase 8/radiation effects , Caspase 9/drug effects , Caspase 9/metabolism , Caspase 9/radiation effects , Cell Line, Tumor , Deoxycytidine/pharmacology , Enzyme Activation/drug effects , Enzyme Activation/radiation effects , Flow Cytometry , Humans , In Situ Nick-End Labeling , Membrane Potential, Mitochondrial , Polymerase Chain Reaction , Gemcitabine
2.
Int J Hyperthermia ; 23(4): 353-61, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17558734

ABSTRACT

Hyperthermia is a useful adjunct in cancer therapy as it can increase the effectiveness and decrease the toxicity of currently available cancer treatments such as chemotherapy and radiation. In the present study, we investigated whether 41 degrees C hyperthermia (mild HT) for 20 min can enhance macrosphelide (MS5)-induced apoptosis in human lymphoma U937 cells. Our results revealed that, compared with MS5 (5 microM) and mild HT alone, the combined treatment exhibited significant enhancement in apoptosis at 6 h, which was evaluated by observing morphological changes and DNA fragmentation. Marked increase in the reactive oxygen species (ROS) generation was observed immediately after the combined treatment. Significant increase in Fas externalization, caspase-8 and caspase-3 activation, and loss of mitochondrial membrane potential (MMP) was found after the combined treatment compared with MS5 and mild HT alone. Moreover, this combination can also alter the expression of apoptosis-related proteins as evident by the cleavage of Bid and down-regulation of Bcl-2 while no change in the expression of Bax was observed. Furthermore, an immediate rise in the intracellular calcium ion ([Ca(2+)]i) concentration was observed after the combined treatment, which continuously increased in a time-dependent manner. In addition, mild HT treatment alone also increases [Ca(2+)]i concentration without inducing apoptosis. Our data indicate that early increase in ROS generation is mainly responsible for the enhancement of apoptosis after the combined treatment.


Subject(s)
Antineoplastic Agents/therapeutic use , Apoptosis , Hot Temperature , Hyperthermia, Induced , Apoptosis/drug effects , Apoptosis/radiation effects , BH3 Interacting Domain Death Agonist Protein/metabolism , BH3 Interacting Domain Death Agonist Protein/radiation effects , Calcium/metabolism , Calcium/radiation effects , Caspase 3/metabolism , Caspase 3/radiation effects , Caspase 8/metabolism , Caspase 8/radiation effects , Combined Modality Therapy , Gene Expression Regulation/radiation effects , Heterocyclic Compounds/therapeutic use , Humans , Membrane Potential, Mitochondrial/drug effects , Membrane Potential, Mitochondrial/radiation effects , Proto-Oncogene Proteins c-bcl-2/radiation effects , Reactive Oxygen Species/metabolism , Reactive Oxygen Species/radiation effects , Time Factors , U937 Cells , bcl-2-Associated X Protein/metabolism , bcl-2-Associated X Protein/radiation effects
SELECTION OF CITATIONS
SEARCH DETAIL
...